Zingerone-encapsulated solid lipid nanoparticles: Negatively charged surface containing solid lipid nanoparticles that can encapsulate zingerone bind to inflammation-associated proteins in vitro.
Currently, various anti-inflammatory drugs are used in intestinal bowel disease (IBD) treatment as first-line management therapies. Although beneficial effects were observed with these drugs, unwanted exposure to healthy tissue causes side-effects. Therefore, targeted delivery of anti-inflammatory drugs to the inflamed tissue is still an unmet need. Herein, we have developed solid lipid nanoparticles with negative surface charge that can specifically adhere to transferrin, a protein that overexpressed at the inflamed tissue. Zingerone, a natural product based anti-inflammatory agent, has been encapsulated into solid lipid nanoparticles (Zin-SLNPs) and protected from the degradation by stomach and intestinal fluids. The Zin-SLNPs consists of 250–350 nm in size, have negative surface charge (-44.08 mV). These Zin-SLNPs have shown appreciable cyto-compatibility, they did not show any cytotoxicity even as high as 1000 μM concentration. Native zingerone and zingerone that released from Zin-SLNPs show efficient anti-inflammatory property by reducing the production of pro-inflammatory cytokines from lipopolysaccharide (LPS)-induced RAW 264.7 macrophages, in vitro. Based on these results, in the future studies, Zin-SLNPs could be tested for their potential therapeutic efficacy in ulcerative colitis in vivo model.Zum Volltext